Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells

Prostate cancer (PCa) is the second most common malignancy and is the fifth leading cause of cancer mortality among men globally. Docetaxel‐based therapy remains the first‐line treatment for metastatic castration‐resistant prostate cancer. However, dose‐limiting toxicity including neutropenia, myelo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cellular and molecular medicine 2021-09, Vol.25 (17), p.8187-8200
Hauptverfasser:	Nalairndran, Geetha, Chung, Ivy, Abdul Razack, Azad Hassan, Chung, Felicia Fei‐Lei, Hii, Ling‐Wei, Lim, Wei‐Meng, Looi, Chin King, Mai, Chun‐Wai, Leong, Chee‐Onn
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen receptors Antineoplastic Agents - pharmacology Apoptosis Apoptosis - drug effects Azetidines - pharmacology baricitinib Cancer therapies Castration Cell Line, Tumor Cluster analysis Docetaxel - pharmacology Drug dosages Drug Resistance, Neoplasm - drug effects Drug Synergism Genes Humans JAK1 Janus kinase Janus Kinase 1 - antagonists & inhibitors Janus kinase 2 Kinases Lethality Male Malignancy Metastases Metastasis Myelosuppression Neurotoxicity Neutropenia Nitriles - pharmacology Original Plasmids Prostate cancer Prostatic Neoplasms - drug therapy Proteins Purines - pharmacology Pyrazoles - pharmacology Pyrimidines - pharmacology RNAi screen ruxolitinib Software Sulfonamides - pharmacology Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!